Patients with inflammatory bowel diseases (IBD) frequently have extraintestinal manifestations including arthritis, sacroiliitis, and ankylosing spondylitis. While the treatment of these rheumatological conditions with traditional non-steroidal anti-inflammatory drugs (NSAIDs) has been reported to lead to frequent IBD exacerbation, the safety of cyclooxygenase-2 (COX-2) inhibitors (Coxibs) remains unclear.

Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis

RIBALDONE, Davide Giuseppe;FAGOONEE, SHARMILA;DE ANGELIS, CLAUDIO GIOVANNI;SMEDILE, Antonina;CAVIGLIA, GIAN PAOLO;PELLICANO, Rinaldo
2015-01-01

Abstract

Patients with inflammatory bowel diseases (IBD) frequently have extraintestinal manifestations including arthritis, sacroiliitis, and ankylosing spondylitis. While the treatment of these rheumatological conditions with traditional non-steroidal anti-inflammatory drugs (NSAIDs) has been reported to lead to frequent IBD exacerbation, the safety of cyclooxygenase-2 (COX-2) inhibitors (Coxibs) remains unclear.
18
6
599
607
Ribaldone, Davide Giuseppe; Fagoonee, Sharmila; Astegiano, Marco; Deangelis, Claudio; Smedile, Antonina; Caviglia, Gian Paolo; Petrini, Elisa; Greco, Anna; Pellicano, Rinaldo
File in questo prodotto:
File Dimensione Formato  
2015;18;599-607.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 258.08 kB
Formato Adobe PDF
258.08 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1529899
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 14
social impact